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Other names: C1orf28; FLJ23316; HPT-JT; HRPT2 
Location: 1q31.2 
Note: Defects in CDC73 are the cause of 
hyperparathyroidism-jaw tumor syndrome. Mutations 




17 exons (all coding). 
Transcription 
CDC73 encodes a 2.7 kb mRNA with a 1596 bp ORF. 








Nuclear, bipartite nuclear localization signal. 
Function 
CDC73 is a tumor suppressor gene encoding a protein 
called parafibromin. Parafibromin is a member of the
human RNA polymerase II-associated complex, Paf1. 
The human Paf1 complex is composed of parafibromin, 
LEO1, PAF1, and CTR9. Parafibromin's interaction 
with this complex is dependent on its C-terminal 
domain, which is deleted in ca. 80% of clinically 
relevant mutations. 
Homology 
Parafibromin shares 54% identity and 67% similarity 
with the D. melanogaster ortholog and 25% identity 
and 45% similarity with the C. elegans ortholog. There 
were no homologies to known protein domains, but 
moderate identity (32%) and similarity (54%) to theS. 
cerevisiae ortholog, Cdc73. 
Mutations 
Germinal 
Various types of mutations often leading to inactivation 
of protein. 
Somatic 
Various somatic inactivating mutations found in 





HPT-JT is an autosomal dominant, multiple neoplasia 
syndrome. 
Oncogenesis 
HPT-JT syndrome is primarily characterized by 
hyperparathyroidism due to parathyroid tumors.  
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Thirty percent of individuals with HPT-JT also develop 
ossifying fibromas, primarily of the mandible and 
maxilla, which are distinct from the brown tumors 
associated with severe hyperparathyroidism. Kidney 
lesions also occur in HPT-JT as bilateral cysts, renal 
hamartomas or Wilms tumors. 
Familial isolated hyperthyroidism 
Disease 
Familial isolated primary hyperparathyroidism is an
autosomal dominant disorder that can represent an 
early stage of either the multiple endocrine neoplasia 
type 1 (MEN1) or hyperparathyroidism-jaw tumor 
(HPT-JT) syndromes; or alternatively caused by a 
distinct entity involving another locus. 
Sporadic parathyroid carcinoma 
Disease 
These cancers characteristically result in more 
profound clinical manifestations of 
hyperparathyroidism than do parathyroid adenomas. 
Parathyroid carcinomas cause hyperparathyroidism. 
The hyperparathyroidism is usually severe, with high 
serum calcium level, severe bone disease, and renal 
stones. 
Prognosis 
5-years survival rate is between 50% and 70%. 
Oncogenesis 
Loss of parafibromin expression strongly predicts 
parathyroid malignancy 
Sporadic renal tumors 
Cytogenetics 
Loss of heterozygosity (LOH) of HRPT2 was found in 
clear cell, papillary, chromophobe renal cell 
carcinomas, oncocytomas, and Wilms tumors. In 
addition, two novel HRPT2 point mutations were 
detected in clear cell carcinoma and Wilms tumor. 
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